| Region | Year | Indication | Notes |
|---|---|---|---|
| United States | 2003 | Moderate-to-severe allergic asthma | First FDA approval (≥ 12 years; later extended to younger patients) |
| Europe | 2005 | Moderate-to-severe allergic asthma | Initial EMA approval |
| Italy | 2006 | Moderate-to-severe allergic asthma | AIFA reimbursement and clinical use |
| Europe | 2014 | Chronic spontaneous urticaria (CSU) | For patients uncontrolled with H1-antihistamines |
| Italy | 2015 | Chronic spontaneous urticaria (CSU) | AIFA reimbursement |
| Europe | 2020 | Chronic rhinosinusitis with nasal polyps (CRSwNP) | Add-on therapy in severe disease |
| United States | 2020 | Chronic rhinosinusitis with nasal polyps (CRSwNP) | Similar indication to EMA |
| United States | 2024 | IgE-mediated food allergy | Reduction of risk of severe allergic reactions |
AS: Conceptualization, Writing—original draft. EN and CD: Conceptualization, Investigation, Supervision. MC and GWC: Validation, Writing—review & editing. All authors read and approved the submitted version.
Eustachio Nettis, who is an Editorial Board Member, and Giorgio Walter Canonica, who is Editor-in-Chief of Exploration of Asthma & Allergy, were not involved in the peer review or editorial decision-making process for this manuscript. Giorgio Walter Canonica reports having received research grants and/or lecturer or advisory board fees from A. Menarini, AstraZeneca, Celltrion, Chiesi Farmaceutici, Faes, Firma, Genentech, GrandPharma, Guidotti, GlaxoSmithKline, HAL Allergy, Novartis, OM Pharma, Organon, RedMaple, Sanofi-Genzyme, Stallergenes Greer, and Uriach Pharma. The remaining authors declare that they have no conflicts of interest.
Not applicable.
Not applicable.
Not applicable.
Not applicable.
Not applicable.
© The Author(s) 2026.
Open Exploration maintains a neutral stance on jurisdictional claims in published institutional affiliations and maps. All opinions expressed in this article are the personal views of the author(s) and do not represent the stance of the editorial team or the publisher.